Patient undergoing hemodialysis. Chronic kidney disease, stage 5
Conditions
Interventions
Intervention 1: The intervention group will receive alpha-lipoic acid supplements with a dose of 300 mg/day, The duration of the study will be for eight weeks. Intervention 2: The control group will c
Sponsors
Shahrekord University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients (20-80 yr.) with a history of hemodialysis treatment for a minimum of six months Willing to participate in the trial
Exclusion criteria
Exclusion criteria: - Any recent significant changes in patients' lifestyle behaviors (diet, physical activity, stress) - History of consuming any antioxidant or anti-inflammatory dietary supplements less than one month before study enrollment - Possible kidney transplantation - History of alcohol consumption - History of cigarette smoking - Allergies or intolerance to alpha-lipoic acid - History of cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total Antioxidant Capacity. Timepoint: Before and after study. Method of measurement: Laboratory kits.;Tumor necrosis factor- alpha. Timepoint: Before and after study. Method of measurement: Laboratory kits.;Erythroblast Sedimentation Rate. Timepoint: Before and after study. Method of measurement: Laboratory kits.;Interleukin - 6. Timepoint: Before and after study. Method of measurement: Laboratory kits.;C-reactive Protein. Timepoint: Before and after study. Method of measurement: Laboratory kits.;Irisin. Timepoint: Before and after study. Method of measurement: Laboratory kits. | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: Befor and after Study. Method of measurement: Sensitive Balance. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactParisa Javadian
Shahrekord University of Medical Sciences
Outcome results
None listed